Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Status:
Completed
Trial end date:
2019-12-05
Target enrollment:
Participant gender:
Summary
This is an open label, multi-institutional, single arm study of dose escalation phase Ib
cohort, followed by a phase II cohort of anti-PD-1 antibody MK-3475 in combination with
bevacizumab. No randomization or blinding is involved.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Arkadiusz Z. Dudek, MD
Collaborators:
Big Ten Cancer Research Consortium Hoosier Cancer Research Network Merck Sharp & Dohme Corp.